CEO Phillip P. Chan purchases 261,469 shares at blended $0.40 avg; stock down -69.1% from 52-week high, company unprofitable ($-5.1M net income).
Phillip P. Chan, CEO of Cytosorbents Corp, executed 2 separate open-market purchases totaling 261,469 shares for $104,897.59 on 2026-06-12 and 2026-06-15, expanding his holdings by +17.6% to 1,744,432 shares. The blended purchase price of $0.40 is below the current price of $0.43, but the stock has declined -69.1% from its 52-week high of $1.39 and is down -36.8% over the past 90 days. Cytosorbents is unprofitable with net income of $-5.1M against quarterly revenue of $8.9M. His prior CTSO purchase on 2023-12-13 experienced a -24.8% 90-day return, showing no pattern of well-timed entry signals at this ticker. The combination of sustained unprofitability, severe price deterioration, and a prior poorly-timed accumulation at the same company warrants scrutiny of the financial and strategic context surrounding this transaction.